Coloplast A/ S stock (DK0060448595): FDA clears Titan Prime implant for U.S. market

Coloplast A/S shares in Denmark traded broadly stable on Nasdaq Copenhagen on 06/03/2026 as the company reported U.S. FDA approval for its next-generation Titan Prime inflatable penile prosthesis, expanding its urology portfolio in a key market.

Coloplast A/S shares on Nasdaq Copenhagen traded relatively steady on 06/03/2026 after the Danish medtech group announced that the U.S. Food and Drug Administration has approved Titan Prime, its next-generation inflatable penile prosthesis for treatment of erectile dysfunction in men who do not respond to medication, underscoring the importance of the United States as a core growth market for the company according to a press release on the same day.Coloplast investor relations as of 06/03/2026GlobeNewswire as of 06/03/2026

The company highlighted that Titan Prime has received FDA clearance for use in the United States and is intended for men with moderate to severe erectile dysfunction who have not achieved adequate results from conservative therapies, reinforcing Coloplast A/S's positioning in the urology and continence care markets and supporting its long-term strategy to grow its intimate healthcare portfolio in North America.MarketScreener as of 06/03/2026

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Coloplast
• Sector/industry: Medical technology - ostomy, continence and urology care
• Headquarters/country: Humlebæk, Denmark
• Core markets: Europe, North America, selected Asia-Pacific markets
• Key revenue drivers: Ostomy care, continence care, urology and wound and skin care solutions
• Home exchange/listing venue: Nasdaq Copenhagen (COLO B)
• Trading currency: DKK

Coloplast A/S: core business model

Coloplast generates most of its revenue by designing and supplying specialized ostomy, continence, urology and wound-care products that are prescribed for chronic conditions and supported by recurring demand from hospitals, clinics and home-care channels worldwide.

Coloplast A/S in peer comparison

Among European medtech peers, Coloplast A/S competes with companies such as ConvaTec Group on ostomy and continence products and with larger diversified players like B. Braun and Smith & Nephew in wound and urology-related solutions, all of which rely on chronic-care consumables and device portfolios for a significant share of their sales according to their latest annual reports filed in 2025.ConvaTec investor relations as of 03/2025B. Braun company information as of 2025

While Coloplast A/S is more narrowly focused on intimate healthcare than some of these rivals, the FDA-cleared Titan Prime implant adds another specialized device to its urology range and may help it defend market share in the U.S. against both international competitors and niche urology device manufacturers that also target patients with medically refractory erectile dysfunction.Coloplast investor relations as of 06/03/2026

Conclusion

The FDA approval of the Titan Prime inflatable penile prosthesis underscores how Coloplast A/S is extending its urology portfolio in the United States, one of its most important regions for growth and product innovation. In the context of a competitive medtech landscape that includes both focused peers like ConvaTec and diversified device manufacturers, the launch may support Coloplast A/S's efforts to differentiate through specialized intimate healthcare solutions without fundamentally altering its role as a chronic-care focused Danish medtech company.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.